ATF4-PHGDH targeting sensitizes FLT3-ITD+ AML to cytarabine [10], overcomes FGFR1/glutaminase inhibitor resistance [25], and normalizes vasculature to potentiate CAR-T efficacy in glioblastoma [13]. The gene discussed is FLT3; the disease is glioblastoma.